Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · IEX Real-Time Price · USD
1.170
+0.020 (1.74%)
At close: Jul 19, 2024, 4:00 PM
1.220
+0.050 (4.27%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Clearside Biomedical Revenue
Clearside Biomedical had revenue of $8.45M in the twelve months ending March 31, 2024, with 758.94% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $230.00K with 5,650.00% year-over-year growth. In the year 2023, Clearside Biomedical had annual revenue of $8.23M with 519.89% growth.
Revenue (ttm)
$8.45M
Revenue Growth
+758.94%
P/S Ratio
10.34
Revenue / Employee
$281,733
Employees
30
Market Cap
87.44M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.23M | 6.90M | 519.89% |
Dec 31, 2022 | 1.33M | -28.25M | -95.51% |
Dec 31, 2021 | 29.58M | 21.68M | 274.65% |
Dec 31, 2020 | 7.89M | 5.72M | 263.28% |
Dec 31, 2019 | 2.17M | 2.14M | 7,143.33% |
Dec 31, 2018 | 30.00K | -315.00K | -91.30% |
Dec 31, 2017 | 345.00K | -175.00K | -33.65% |
Dec 31, 2016 | 520.00K | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alpha Teknova | 36.85M |
CASI Pharmaceuticals | 33.88M |
Hyperfine | 11.69M |
BeyondSpring | 1.75M |
Benitec Biopharma | 7.00K |
CLSD News
- 11 days ago - Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board - GlobeNewsWire
- 25 days ago - Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery - GlobeNewsWire
- 26 days ago - Why Is Clearside Biomedical Stock Gaining Today? - Benzinga
- 5 weeks ago - Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting - GlobeNewsWire
- 2 months ago - Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA® - GlobeNewsWire
- 2 months ago - Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference - GlobeNewsWire
- 2 months ago - Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 - GlobeNewsWire